Former EVP, Chief of Corporate Communications, Investor Relations Officer (4) · SAB Biotherapeutics, Inc. (SABS)

Melissa Ullerich

FY2021 is the first fiscal year CompBrief holds for Melissa Ullerich as a named executive officer of SAB Biotherapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$1,393,073

Salary $256,196Stock awards $0

2nd of 3 named executive officers at SAB Biotherapeutics by FY2021 total.

3 named officers on file for SAB Biotherapeutics, FY2021

Melissa Ullerich’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 1 equity grant, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how SAB Biotherapeutics’s whole pay program stands against its peers

  • SAB Biotherapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on SABS→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed May 25, 2022 (DEF 14A).

Free

Get Melissa Ullerich’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Melissa Ullerich compensation by year

SAB Biotherapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as SAB Biotherapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021
Salary$256,196
Bonus$0
Stock awards$0
Option awards$870,751
Non-equity incentive$266,126
Pension and deferred compensation$0
All other$0
Total$1,393,073

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: SAB Biotherapeutics, Inc. DEF 14A filed May 25, 2022, accession 0000950170-22-010672, and prior-year filings. Open the filing on EDGAR.

How this page was built: the SAB Biotherapeutics, Inc. filed document, accession 0000950170-22-010672. Every figure is read from that document and cited to the page and table it appears in. Filed May 25, 2022.

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
Option43,621—$4.04

Per the Outstanding Equity Awards at Fiscal Year-End table in SAB Biotherapeutics, Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.

SAB Biotherapeutics’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
Samuel ReichExecutive Chairman of the Board of Directors$2,795,626
Melissa Ullerich · this pageFormer EVP, Chief of Corporate Communications, Investor Relations Officer (4)$1,393,073
Eddie SullivanPresident and Chief Executive Officer$526,821

The full SAB Biotherapeutics compensation record

free company brief

This page is one person within SAB Biotherapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are SAB Biotherapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Melissa Ullerich's compensation dossier · One-time report. No refunds.